First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven ...
Association of high histone H3K4 trimethylation level and prognosis of patients with low-TNM-stage hepatocellular carcinoma. Background: Despite survival benefit in patients with advanced HCC, ...
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer Atezolizumab data from clinical trials in non–small-cell lung cancer, metastatic urothelial carcinoma, ...
Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in ...
The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumour size and response to treatment, has been published today (Tuesday 20 January) in a special ...
CHICAGO -- FDA researchers found that when evaluating outcomes observed with immunotherapy drugs used in advanced melanoma, the depth of response (i.e., how much of the cancer is eliminated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results